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JapanBackground: Broad use of monovalent Haemophilus influenzae type b (Hib) conjugate vaccines based on
the capsular polysaccharide polyribosyl-ribitol phosphate (PRP), has significantly reduced invasive Hib
disease burden in children worldwide, particularly in children aged <1 year. In Japan, PRP conjugated
to tetanus toxoid (PRP-T) vaccine has been widely used since the initiation of public funding programs
followed by a routine vaccination designation in 2013.
Methods: We compared the immunogenicity and safety of PRP conjugated to a non-toxic diphtheria toxin
mutant (PRP-CRM197) vaccine with the PRP-T vaccine when administered subcutaneously to healthy
Japanese children in a phase III study. Additionally, we evaluated the immunogenicity and safety profiles
of a diphtheria–tetanus acellular pertussis (DTaP) combination vaccine when concomitantly
administered with either PRP-CRM197 or PRP-T vaccines. The primary endpoint was the ‘‘long-term sero-
protection rate”, defined as the group proportion with anti-PRP antibody titersP1.0 lg/mL, after the pri-
mary series.
Results: Long-term seroprotection rates were 99.3% in the PRP-CRM197 group and 95.6% in the PRP-T
group. The intergroup difference (PRP-CRM197 group – PRP-T group) was 3.7% (95% confidence interval:
0.099–7.336), demonstrating that PRP-CRM197 vaccine was non-inferior to PRP-T vaccine (p < 0.0001).
Furthermore, the ‘‘short-term seroprotection rate” (anti-PRP antibody titerP0.15 lg/mL) before booster
vaccination was higher in the PRP-CRM197 group than in PRP-T. Concomitant administration of PRP-
CRM197 vaccine with DTaP vaccine showed no differences in terms of immunogenicity compared with
concomitant vaccination with PRP-T vaccine and DTaP vaccine. Although CRM197 vaccine had higher local
reactogenicity, overall, both Hib vaccines had acceptable safety and tolerability profiles.
Conclusion: The immunogenicity of PRP-CRM197 vaccine administered subcutaneously as a three-dose
primary series in children followed by a booster vaccination 1 year after the primary series induced pro-
tective levels of Hib antibodies with no safety or tolerability concerns.
Clinical trial registry: Registered on ClinicalTrials.gov: NCT01379846
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Haemophilus influenzae type b (Hib) is a Gram-negative bac-
terium that can cause severe diseases (invasive Hib diseases) such
as meningitis, pneumonia, epiglottitis, and sepsis in children
mainly younger than 5 years. Of Hib meningitis cases in Japanese
children aged less than 5 years, 46% involve children aged less than1 year [1]. In Japan, recent data showed that the rate of Hib menin-
gitis occurring in children aged less than 6 months is increasing and
that Hib disease may occur in children as young as 2 months of age
[1,2]. Therefore, starting vaccination at a younger age is an impor-
tant strategy to increase the effectiveness of vaccines against inva-
sive Hib disease. In Japan, the routine schedule of Hib vaccination is
as follows: infants receive three doses between 2 and 6 months of
age as a primary series, and a booster dose is recommended at
7 months or later after completion of the primary series.
4636 T. Togashi et al. / Vaccine 34 (2016) 4635–4641It is reported that Hib conjugate vaccines have reduced the inci-
dence of invasive Hib disease by approximately 90% in those coun-
tries where Hib vaccination has been introduced within the
national immunization program [3], demonstrating the impor-
tance of Hib vaccination. In response to the public health concerns
of Hib disease, and based on the very high effectiveness of Hib con-
jugate vaccines in preventing infection, the World Health Organi-
zation (WHO) has recommended increased routine Hib
vaccination coverage worldwide [3].
As of January 2015, a vaccine containing polyribosyl-ribitol
phosphate (PRP) conjugated to tetanus toxoid (PRP-T) (Sanofi Pas-
teur S.A., Lyon, France) is the only Hib vaccine marketed in Japan.
From 2008 to 2013 it was administered as a voluntary vaccination
and coverage increased from 5% to 10% in January 2010 to 36% in
January 2012 [4,5]. The mean annual incidence of Hib meningitis
in those aged <5 years decreased from 7.7 per 100,000 between
2008 and 2010 to 0 per 100,000 in 2014 [6]. During this period,
Hib vaccine coverage increased in Japan, supporting the observed
reduction in the incidence of Hib meningitis [7]. Subsequently,
routine Hib immunization in Japan was recommended in 2013,
and therefore, Hib conjugate vaccine demand has increased signif-
icantly. In light of this recommendation and increased demand, a
second licensed and marketed Hib vaccine might contribute to
ensuring a stable Hib vaccine supply for the Japanese population.
Many clinical studies have demonstrated that PRP-CRM197 has
good immunogenicity, safety, and tolerability profiles [8–10].
PRP-CRM197 vaccine has been licensed and marketed in multiple
countries, and is designated as a WHO prequalified vaccine that
is also supplied via the WHO and the United Nations [11].
The primary objective of this study was to demonstrate the
non-inferiority of PRP-CRM197 vaccine compared with PRP-T vac-
cine by measuring anti-PRP antibodies and determining long-
term anti-PRP seroprotection rates (titerP 1.0 lg/mL [12]) after
a primary series of subcutaneous vaccinations in healthy Japanese
children. The immunogenicity and safety profile of PRP-CRM197
vaccine and diphtheria, tetanus, and acellular pertussis (DTaP) vac-
cine when administered concomitantly in Japanese healthy chil-
dren was also evaluated.2. Materials and methods
2.1. Study design and subjects
This phase III, randomized, observer-blind, multicenter,
parallel-group study was conducted at 34 sites in Japan (listed in
the Acknowledgements) between June 2011 (when the first patient
signed the informed consent form) and February 2013 (the last
subject’s final study visit). Study subjects were healthy Japanese
children aged 3–6 months at time of the first dose, who were
enrolled by investigators and randomized at a 2:1 ratio to receive
PRP-CRM197 vaccine or PRP-T vaccine using a permuted block
schedule. The schedule was generated with a specified block size
and kept by an independent randomization officer. Subjects and
investigators were masked using an observer-blind method.
The Institutional Review Board of each study site approved the
study, which was performed in accordance with the Declaration of
Helsinki and Good Clinical Practice standards. The subjects’ par-
ents/legal guardians provided written informed consent to partic-
ipate in the trial before enrolment.
Exclusion criteria included: serious acute illness or chronic
disease; previous disease that was suspected to be caused by
Hib, diphtheria, tetanus or pertussis; previous diagnosis of immun-
odeficiency; any known history of anaphylaxis to ingredients of the
study vaccines; history of convulsions; or previous administrationof another Hib vaccine/other vaccines containing components of
DTaP vaccines.
2.2. Vaccine
PRP-CRM197 vaccine (lots: H816-005-02 and H816-005-03)
consists of 10 lg of PRP conjugated to a non-toxic mutant of diph-
theria toxoid—diphtheria cross reactive material, (CRM197)—and
contains 0.3 mg of aluminum phosphate adjuvant (VAXEMTM Hib,
produced by Novartis Vaccine and Diagnostics, now a GSK com-
pany, and licensed by Takeda Pharmaceutical Company Limited
for use in Japan). PRP-T vaccine (lots: G1154, and G1346) consists
of 10 lg of PRP conjugated to tetanus toxoid (ActHIB; Sanofi Pas-
teur S.A., Lyon, France). PRP-CRM197 vaccine is supplied as a fully
liquid component and PRP-T as a lyophilized pellet that must be
reconstituted in 0.5 mL sterile saline immediately before use. The
DTaP vaccine (lots: V069C and V081A) contains diphtheria toxoid
(15Lf), tetanus toxoid (2.5Lf), acellular pertussis toxin, and fila-
mentous hemagglutinin (P4 protective pertussis units), with
0.1 mg of aluminum hydroxide adjuvant (Adsorbed Diphtheria–
Purified Pertussis–Tetanus Combined Vaccine Kit TAKEDA).
PRP-CRM197 vaccine (0.5 mL) and PRP-T vaccine (0.5 mL) were
administered subcutaneously according to routine practice in
Japan in the primary series and booster vaccination in the deltoid
region of the outer aspect of the upper arm. The DTaP vaccine
was administered concomitantly by subcutaneous injection in
the contralateral arm. Intervals between the three doses in the
primary series were 3–8 weeks, the booster vaccine being admin-
istered approximately 1 year after the primary series. Investigators
and parents/guardians, but not clinical staff administering the
vaccine, were blinded as to whether PRP-CRM197 vaccine or PRP-
T vaccine was injected.
2.3. Evaluation procedures
Four blood samples (3 mL) for immunogenicity assessment
were obtained from the subjects before the first vaccination, at
4 weeks after the third vaccination, before booster vaccination,
and at 4 weeks after the booster dose. Anti-PT, and anti-FHA anti-
bodies were measured by enzyme-linked immunosorbent assay
(ELISA). Anti-diphtheria toxoid antibodies were measured by the
immunoneutralization test. Anti-tetanus toxoid was measured
using the Kaketsuken particle agglutination method. Immuno-
genicity against Hib was determined by measuring ELISA anti-
PRP titers, which were reflective of the protective rate: anti-PRP
titer P1.0 lg/mL standard long-term protective threshold and
P0.15 lg/mL standard short-term protective threshold [3,12,13].
Safety monitoring was performed using a diary card completed
by the parents or legal guardians including solicited injection site
adverse events (erythema, swelling, induration, and pain), sys-
temic adverse events (rash, irritability, abnormal crying, decreased
appetite, vomiting, diarrhea, somnolence, and sleeplessness), and
axillary temperature for 14 days after each vaccination.
Safety was evaluated using System Organ Class and Preferred
Terminology of Medical Dictionary for Regulatory Activities (Med-
DRA) for all adverse events (AEs) and by examining the causal rela-
tionship (‘‘adverse reactions” are those that are judged by the
investigator to be related to vaccination), outcome, severity, time
of onset (from time of last injection), and duration. AEs were mon-
itored during the study period from the signing of the informed
consent form to 4 weeks after the third vaccination, and from the
booster vaccination to 4 weeks after the booster injection. Serious
AEs (defined as any untoward medical occurrence after any dose
that results in death, is life threatening, requires in-patient hospi-
talization or prolongation of existing hospitalization, results in
T. Togashi et al. / Vaccine 34 (2016) 4635–4641 4637persistent or significant disability/incapacity, or led to a congenital
anomaly/birth defect) were monitored throughout the study until
the last study visit.
2.4. Statistical analysis
This study was designed to test the non-inferiority of PRP-
CRM197 vaccine compared with PRP-T vaccine with respect to
anti-PRP antibody expressed as seroprotection rate (proportions
with titer P1.0 lg/mL) at 4 weeks after the third dose of the pri-
mary series (primary immunogenicity variable). The study sample
size was determined as follows. The anti-PRP antibody seroprotec-
tion rate (titerP 1.0 lg/mL) at 4 weeks after the third dose of the
primary series of PRP-CRM197 or PRP-T vaccine was estimated to be
92.0%. For comparison of the anti-PRP antibody seroprotection rate
between PRP-CRM197 and PRP-T groups with a randomization ratio
of 2:1, 90% power and a non-inferiority margin of 10%, the mini-
mum numbers of evaluable subjects required in the PRP-CRM197
and PRP-T groups were 234 and 117, respectively; therefore, 270
and 135 were recruited to anticipate a 10–15% dropout rate.
The non-inferiority margin of 10% was based on WHO guideli-
nes [14]. Non-inferiority would be declared if the result of the
non-inferiority chi-square test with a margin of 10% was statisti-
cally significant, at a significance level of 5%.
Immunogenicity was assessed in all subjects who were
randomized and received at least one dose of the study vaccine.
For the primary immunogenicity variable, a non-inferiority
chi-square test was performed and the treatment difference
(PRP-CRM197 vs. PRP-T) and two-sided 95% confidence interval
(CI) were calculated. Point estimates and 95% CIs for each group
were also calculated. Similar analyses were performed for
anti-PRP antibody seroprotection rates (titerP 0.15 lg/mL). With
regard to the anti-PRP antibody, the geometric mean titer (GMT)
and 95% CI were calculated for each group, and the geometric mean
ratio (GMR, PRP-CRM197/PRP-T) and 95% CI were also calculated.
Safety was assessed in all subjects who received at least one dose
of the study vaccine. Statistical analyses were performed using
SAS Ver. 9.2 (SAS Institute Inc., Cary, NC, USA).Enrolled infants n = 416 
PRP-CRM197 group n = 278 
Disconnued n = 15
adverse event n = 1
loss to follow-up n = 1 
major protocol deviaon n = 3
voluntary withdrawal n = 10
First vaccinaon of 
priming series n = 278
Booster vaccinaon n = 263
Completed study n = 262
Disconnued n = 1
Adverse event n = 1
Fig. 1. Study e3. Results
3.1. Enrolment of study participants
A total of 416 subjects were enrolled: 278 were randomized
into the PRP-CRM197 group and 138 into the PRP-T group (Fig. 1).
One subject in the PRP-T group was withdrawn by the parents
between randomization and receiving the first dose. Therefore, a
total of 415 subjects were included in the immunogenicity and
safety analyses, of whom 411 completed the primary series and
393 completed the booster vaccination. The mean subject age
was 4.25 months, and there was no significant difference in the
characteristics of subjects in the two groups (Table 1).3.2. Immunogenicity
The long-term anti-PRP seroprotection rate (P1.0 lg/mL) at
4 weeks after the primary series was 99.3% (273/275) in the
PRP-CRM197 group and 95.6% (129/135) in the PRP-T group. The
difference in seroprotection rate between the groups was 3.7%
(two-sided 95% CI: 0.10–7.34%), demonstrating the non-
inferiority of PRP-CRM197 vaccine compared with PRP-T vaccine
(non-inferiority chi-square test: p < 0.0001) (Fig. 2).
The short-term anti-PRP seroprotection rate (P0.15 lg/mL) at
4 weeks after the primary series was 100% in both groups. At
4 weeks after the primary series, the GMT for the anti-PRP anti-
body was 18.00 lg/mL in the PRP-CRM197 group and 8.67 lg/mL
in the PRP-T group (Table 2). Based on the GMR of PRP-CRM197/
PRP-T of 2.08 (two-sided 95% CI: 1.681–2.562), the GMT was sig-
nificantly (approximately two-fold) higher in the PRP-CRM197 vac-
cine group than in the PRP-T group.
Anti-PRP antibodies persisted such that the short-term anti-PRP
seroprotection rate (P0.15 lg/mL) before booster administration
was significantly higher in the PRP-CRM197 group than in the
PRP-T group (93.2% vs. 86.2%, group difference: 7.0%, two-sided
95% CI: 0.33–13.68). However, there was no significant difference
in long-term seroprotection rate (P1.0 lg/mL) before the booster.PRP-T group n = 138
Disconnued n = 7
voluntary withdrawal n = 6  
longer dosing interval than
speciﬁed n = 1
First vaccinaon of 
priming series n = 137
Booster vaccinaon n = 130
Completed study n = 130
Disconnued n = 1
voluntary withdrawal n = 1
nrolment.
Table 1
Characteristics of subjects.
Total
(N = 416a)
PRP-CRM197
(N = 278)
PRP-T
(N = 138a)
Age (months) (%)
<4 40.1 (167) 40.3 (112) 39.9 (55)
4–5 34.6 (144) 34.2 (95) 35.5 (49)
P5 25.2 (105) 25.5 (71) 24.6 (34)
Mean (SD) 4.25 (0.98) 4.25 (0.98) 4.27 (0.99)
Range (Min, Max) 3.0, 6.9 3.0, 6.9 3.0, 6.7
Sex (%N)
Male 53.1 (221) 52.5 (146) 54.3 (75)
Female 46.9 (195) 47.5 (132) 45.7 (63)
Height (cm)
Mean (SD) 62.9 (3.04) 62.9 (3.03) 63.0 (3.09)
Range (Min, Max) 55, 79 55, 73 56, 79
Weight (kg)
Mean (SD) 6.87 (0.91) 6.91 (0.96) 6.79 (0.82)
Range (Min, Max) 4.4, 10.1 4.4, 10.1 4.7, 9.2
Anti-PRP antibody titer before primary series (lg/mL) (%)
Min– <0.15 67.2 (279) 65.5 (182) 70.8 (97)
P0.15–Max 32.8 (136) 34.5 (96) 29.2 (40)
N: Number of subjects, SD: Standard deviation, Min: Minimum, Max: Maximum.
a One subject was excluded from analysis. N = 137 for PRP-T Anti-PRP data and
safety data (and total N = 415).
4638 T. Togashi et al. / Vaccine 34 (2016) 4635–4641Similar to the primary series, the anti-PRP antibody short-term
seroprotection rate (titerP 0.15 lg/mL) at 4 weeks after booster
vaccinationwas 100% inboth groups. Thus, booster vaccinationwith
PRP-CRM197 also demonstrated comparable immunogenicity with
PRP-T. The long-term anti-PRP seroprotection rate (titerP 1.0 lg/mL)
at 4 weeks after booster vaccination was comparable between the
groups (PRP-CRM197: 99.2% and PRP-T: 100%), with a group differ-
ence of 0.8% (two-sided 95% CI: 1.81–0.29%) (Fig. 2).
The potential interference between DTaP and the study vaccines
was also investigated, given the concomitant use according to the
recommended immunization schedule in Japan. The seroprotection
rates with the DTaP vaccine were comparable between the PRP-
CRM197 and PRP-T groups. At 4 weeks after the primary immuniza-
tion, the seroprotection rates of the PRP-CRM197 and PRP-T groups,
respectively, were 99.6% and 97.8% for the anti-diphtheriaFig. 2. Antibody seroprotection rate based on anti-PRPantibody; 87.3% and 91.1% for the anti-pertussis antibody (anti-
PT titers); 96.7% and 94.8% for the anti-pertussis antibody (anti-
FHA titers); and 100% and 100% for the anti-tetanus antibody.
3.3. Safety
In this study, no deaths were observed in either group. The pro-
portions of serious AEs were similar between the groups. All seri-
ous events were considered unrelated to the study vaccine. The
proportions of AEs were similar between the groups: 98.2%
(273/278 subjects) in the PRP-CRM197 group and 98.5% (135/137
subjects) in the PRP-T group. In this study, common AEs (fre-
quencyP 20%) in the PRP-CRM197 and PRP-T groups, respectively,
included injection site erythema (83.8%, 81.0%), injection site
induration (74.8%, 66.4%), injection site swelling (59.0%, 48.2%),
nasopharyngitis (37.4%, 41.6%), upper respiratory tract inflamma-
tion (28.8%, 28.5%), diarrhea (26.6%, 20.4%), and bronchitis
(20.5%, 28.5%).
The proportions of systemic reactions were similar in both
groups. Although there was a higher proportion of injection site
reactions in the PRP-CRM197 group than in the PRP-T group, all
injection site reactions were mild and transient in both groups.
Furthermore, the proportion of injection site reactions in the
PRP-CRM197 group was similar to that in the DTaP group (both vac-
cines contain an aluminum adjuvant). The proportions of severe
injection site reactions (>50 mm) for the PRP-CRM197 and PRP-T
groups, respectively, were: 8.3% and 1.5% for erythema; 5.4% and
1.5% for swelling; and 2.9% and 0% for induration. The overall pro-
portion of adverse reactions for the PRP-CRM197 group (82.4%,
229/278) was higher than that for the PRP-T group (62.0%,
85/137 subjects), owing to the higher proportion of injection site
reactions. However, the overall proportion of adverse reactions,
other than injection site reactions, was similar in both groups
(Figs. 3 and 4).
4. Discussion
This study evaluated the immunogenicity and safety of a pri-
mary series plus booster of subcutaneous vaccinations using PRP-
CRM197 vaccine in healthy Japanese children compared withantibody titers (P1.0 lg/mL and P0.15 lg/mL).
Table 2
GMT and GMR for anti-PRP antibody titers at 4 weeks after the primary series and 4 weeks after the booster vaccination.
PRP-CRM197 PRP-T GMR
(PRP-CRM197/PRP-T)
Before the primary series N
GMT
Geometric SD
95% CI
278
0.18
2.34
[0.16–0.20]
137
0.17
2.17
[0.15–0.20]
1.06
[0.89–1.25]
4 weeks after the primary series N
GMT
Geometric SD
95% CI
275
18.0a
2.66
[16.0–20.2]
135
8.67
3.02
[7.19–10.5]
2.08
[1.68–2.56]
Before the booster N
GMT
Geometric SD
95% CI
263
0.91
3.22
[0.79–1.05]
130
0.70
3.49
[0.56–0.87]
1.30
[1.01–1.67]
4 weeks after the booster N
GMT
Geometric SD
95% CI
263
32.2
2.86
[28.3–36.6]
130
35.1
2.69
[29.6–41.7]
0.92
[0.74–1.14]
N: Number of subjects; GMT: geometric mean titers of anti-PRP antibody (lg/mL); data in square brackets indicate two-sided 95% confidence interval [CI].
a Approximately two-fold higher compared with the PRP-T group.
Fig. 3. Proportions of local adverse reactions.
Fig. 4. Proportions of systemic adverse reactions.
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currently used DTaP vaccine.
The result of this phase III study shows that PRP-CRM197 vaccine
elicits immune responses indicative of short- and long-term pro-
tection against invasive Hib disease that meet the WHO criteria
of short- (P0.15 lg/mL) and long-term (P1.0 lg/mL) seroprotec-
tion rates [3,12,13]. Non-inferiority was demonstrated between
PRP-CRM197 vaccine and PRP-T vaccine in the proportion of sub-
jects with an anti-PRP titer P1.0 lg/mL, measured 4 weeks after
completion of the primary series. Furthermore, while this study
was only statistically powered to evaluate non-inferiority as the
primary objective, the serological assay parameters (GMT, seropro-
tection rates) for PRP-CRM197 vaccine were generally comparable
with those for PRP-T vaccine 4 weeks after the primary series
and immediately before the booster. In addition, seroprotection
rates before booster vaccination were higher in subjects vaccinated
with PRP-CRM197 vaccine than with PRP-T. Increased protection in
the period before booster vaccination is relevant because it coin-
cides with the most typical age for invasive Hib disease (meningi-
tis), which most often occurs between birth and approximately
1 year of age.
This study also showed that PRP-CRM197 vaccination was gener-
ally safe and well tolerated. Although the proportion of mild to
moderate injection site reactions caused by PRP-CRM197 vaccina-
tion was higher than that in the PRP-T group, it was similar to that
induced by the licensed DTaP vaccine alone. This result was
expected because the subcutaneous administration (i.e., standard
route for childhood immunization in Japan) of aluminum-
containing vaccines like PRP-CRM197 and DTaP is known to be
more reactogenic than the intramuscular route. As expected, the
incidence of injection site reactions in this study was higher than
that reported in previous studies in which PRP-CRM197 vaccine
was administered intramuscularly [9,11,15–18].
Compared with intramuscular vaccination in other countries,
most inactivated vaccines for children are administered subcuta-
neously in Japan.
In Japan, the Hib and DTaP-based combination vaccines are
usually administered in a synchronized schedule. In this study,
concomitant vaccination with PRP-CRM197 and DTaP vaccine
showed no differences in terms of immunogenicity compared
with concomitant vaccination with PRP-T and DTaP vaccine. There
were no major safety concerns in either vaccine group using
subcutaneous administration.
4640 T. Togashi et al. / Vaccine 34 (2016) 4635–4641The results of this study should be considered in light of its lim-
itations. In this study, the PRP-CRM197 and DTaP vaccines were
administered concomitantly, but the DTaP vaccine was replaced
with the DTaP-IPV vaccine as a standard vaccination in Japan dur-
ing the study period. Thus, our results may differ from those in
actual practice using the PRP-CRM197 vaccine concomitantly with
the DTaP-IPV vaccine. However, the results obtained with other
vaccine combinations including PRP-CRM197 provide support for
its efficacy. In one clinical study, PRP-CRM197 was administered
concomitantly with oral polio vaccine [19]. It was concluded that
PRP-CRM197 was safe and well tolerated, and that it induced a good
PRP antibody response in healthy children.
This study confirmed that a primary series and booster vaccina-
tion with PRP-CRM197 vaccine has no major safety or tolerability
concerns and induced protective levels of antibodies against inva-
sive Hib disease in children. Although PRP-CRM197 vaccine resulted
in higher local reactogenicity, PRP-CRM197 vaccine is comparable
with licensed PRP-T vaccine in terms of immunogenicity and over-
all safety. The introduction of PRP-CRM197 vaccine as the second
Hib vaccine in Japan will ensure a stable supply of Hib vaccine
and price competition. Therefore, PRP-CRM197 is important for
public health in Japan because it will contribute to securing the
overall coverage of Hib vaccination for Japanese children [20].
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Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
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